VANCOUVER, BC – Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class anti-resistance oncology therapeutic, has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in a validated… Read More
Canadian granting agency MITACS commits to three years of funding for the project’s second stage to optimize certain proprietary microcarrier technologies for use in RepliCel’s cell therapy manufacturing RepliCel signs… Read More
Data fragmentation and a lack of transparency are serious problems in healthcare. A unified overview of a patient’s status (including at home) would assist collaboration within hospitals and reduce costs… Read More
Company also reaffirms data readout timelines for its Phase 2 trial VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug… Read More
Free, Live, 90-minute Medical Device Playbook Event on Thursday, September 23, 2021. Francois Michelon, CEO, ENDRA Life Sciences, and Steven Plymale, Former CEO, MyndTec and Profound Medical, discuss lessons learned… Read More
